Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Switzerland Companies

Former Roche site in Colorado, Corden Pharma, lays off 60 people

This article was originally published in Scrip

Executive Summary

Less than two months after Roche sold its manufacturing facility in Boulder, Colorado, the new owners have announced plans to lay off 60 of its 260 workers. The renamed Corden Pharma Colorado, which was acquired by International Chemical Investors Group (ICIG) in September to incorporate into its Corden Pharma pharmaceutical platform, is to focus on contract manufacturing and development, according to local press reports.

Table

View full table

Topics

Related Companies

Tags:
Switzerland Companies
Latest Headlines

CAR-T To N-of-1 Studies: How Jeeva Is Helping Drive Trial Efficiencies

Legend Buyout Report Boosts, Validates China Biotech

Cardurion Raises $260m To Advance First-In-Class Cardiovascular Drugs

CordenPharma Will Scale Up To Address GLP-1 Shortage

See All
UsernamePublicRestriction

Register

SC014973

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By